🇺🇸 FDA
Pipeline program

CINRYZE

0624-200

Phase 2 mab completed

Quick answer

CINRYZE for Hereditary Angioedema is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Hereditary Angioedema
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials